Dimerix Ltd has released a press release.
Corporate Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Dimerix
- Key Patent Allowed in Japan
- Dimerix Raises $2 million to Advance Clinical Program
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Appointment of Chief Executive Officer
- Update presentation - interim data
Later from Dimerix
- Receipt of $420k Research & Development Tax Refund
- Investor Update
- Research Validates Relevance of DMX Receptor-HIT Technology
- Positive Results from Phase 2a Trial of DMX-200
- DMX-200 tablet manufacture and human study timeline
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix